Pharsight

Application	Filing Date	Opposition Party	Legal Status

EP14815668A	2018-10-30	Epping Hermann Fischer Patentanwaltgesellschaft MBH	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US9248191	January, 2017	Terminated-Settled	Allergan, Inc.	Famy Care Limited
US8642556	January, 2017	FWD Entered	Allergan, Inc.	Teva Pharmaceuticals USA, Inc.
US8642556	January, 2017	Terminated-Settled	Allergan, Inc.	Famy Care Limited
US9248191	January, 2017	Terminated-Dismissed	Allergan, Inc.	Akorn, Inc.
US8629111	January, 2017	Terminated-Dismissed	Allergan, Inc.	Akorn, Inc.
US8629111	January, 2017	Terminated-Settled	Allergan, Inc.	Famy Care Limited
US8642556	January, 2017	FWD Entered	Allergan, Inc.	Akorn, Inc.
US8633162	January, 2017	FWD Entered	Allergan, Inc.	Teva Pharmaceuticals USA, Inc.
US9248191	January, 2017	Terminated-Dismissed	Allergan, Inc.	Teva Pharmaceuticals USA, Inc.
US8685930	January, 2017	Terminated-Dismissed	Allergan, Inc.	Teva Pharmaceuticals USA, Inc.
US8633162	January, 2017	FWD Entered	Allergan, Inc.	Akorn, Inc.
US8629111	January, 2017	Terminated-Dismissed	Allergan, Inc.	Teva Pharmaceuticals USA, Inc.
US8648048	January, 2017	Terminated-Dismissed	Allergan, Inc.	Teva Pharmaceuticals USA, Inc.
US8685930	January, 2017	Terminated-Settled	Allergan, Inc.	Famy Care Limited
US8648048	January, 2017	Terminated-Dismissed	Allergan, Inc.	Akorn, Inc.
US8648048	January, 2017	Terminated-Settled	Allergan, Inc.	Famy Care Limited
US8633162	January, 2017	Terminated-Settled	Allergan, Inc.	Famy Care Limited
US8685930	January, 2017	Terminated-Dismissed	Allergan, Inc.	Akorn, Inc.
US8629111	June, 2016	Terminated-Settled	Allergan, Inc.	Argentum Pharmaceuticals LLC
US8685930	June, 2016	Terminated-Dismissed	Allergan, Inc.	Mylan Pharmaceuticals Inc.
US8642556	June, 2016	FWD Entered	Allergan, Inc.	Mylan Pharmaceuticals Inc.
US8633162	June, 2016	FWD Entered	Allergan, Inc.	Mylan Pharmaceuticals Inc.
US8648048	June, 2016	Terminated-Dismissed	Allergan, Inc.	Mylan Pharmaceuticals Inc.
US9248191	June, 2016	Terminated-Dismissed	Allergan, Inc.	Mylan Pharmaceuticals Inc.
US8629111	June, 2016	Terminated-Dismissed	Allergan, Inc.	Mylan Pharmaceuticals Inc.
US8685930	June, 2015	Terminated-Denied	Allergan, Inc.	Apotex Corp.
US8633162	June, 2015	Terminated-Denied	Allergan, Inc.	Apotex Corp.
US8642556	June, 2015	Terminated-Denied	Allergan, Inc.	Apotex Corp.
US8648048	June, 2015	Terminated-Denied	Allergan, Inc.	Apotex Corp.
US8629111	June, 2015	Terminated-Denied	Allergan, Inc.	Apotex Corp.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8648048	ABBVIE	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (3 months from now)
US8633162	ABBVIE	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (3 months from now)
US9248191	ABBVIE	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (3 months from now)
US8629111	ABBVIE	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (3 months from now)
US8685930	ABBVIE	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (3 months from now)
US8642556	ABBVIE	Methods of providing therapeutic effects using cyclosporin components	Aug, 2024 (3 months from now)
US8292129	ABBVIE	Dispensing device	Feb, 2031 (6 years from now)
US8561859	ABBVIE	Dispensing device	Apr, 2032 (7 years from now)
US9676525	ABBVIE	Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids	Feb, 2034 (9 years from now)
US9669974	ABBVIE	Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids	May, 2034 (10 years from now)

Restasis Multidose is owned by Abbvie.

Restasis Multidose contains Cyclosporine.

Restasis Multidose has a total of 10 drug patents out of which 0 drug patents have expired.

Restasis Multidose was authorised for market use on 23 December, 2002.

Restasis Multidose is available in emulsion;ophthalmic dosage forms.

Restasis Multidose can be used as increase tear production in patients with keratoconjunctivitis sicca (dry eye)., increase tear production to treat patients with keratoconjunctivitis sicca (dry eye)..

The generics of Restasis Multidose are possible to be released after 11 May, 2034.

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 23 December, 2002

Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).; Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).

Dosage: EMULSION;OPHTHALMIC

Pharsight

Restasis Multidose patents expiration

RESTASIS MULTIDOSE family patents

Related content